PORTFOLIO NEWS Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer January 30, 2023 Read More » Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders January 30, 2023 Read More » Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics January 10, 2023 Read More » ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 9, 2023 Read More » NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities January 9, 2023 Read More » Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones January 9, 2023 Read More » Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities January 9, 2023 Read More » Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics January 6, 2023 Read More » Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease January 5, 2023 Read More » eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update January 5, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders January 30, 2023 Read More »
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics January 10, 2023 Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 9, 2023 Read More »
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities January 9, 2023 Read More »
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones January 9, 2023 Read More »
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities January 9, 2023 Read More »
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics January 6, 2023 Read More »
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease January 5, 2023 Read More »
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update January 5, 2023 Read More »
